title: Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.
abstract: Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-alpha (TNF-alpha) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-alpha agents, and periodic monitoring for the development of hepatitis is important.
authors.affiliation: Royal Prince Alfred Hospital, Sydney, NSW, Australia. gmoresearch@excite.com
authors.forename: Gerard
authors.initials: G
authors.lastname: Ozorio
authors.forename: Bruce
authors.initials: B
authors.lastname: McGarity
authors.forename: Haesung
authors.initials: H
authors.lastname: Bak
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Jordan
authors.forename: Henry
authors.initials: H
authors.lastname: Lau
authors.forename: Cathy
authors.initials: C
authors.lastname: Marshall
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology*; D006801:Humans; D000069285:Infliximab; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab